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the study by Yağcıoğlu et al., this study does not 
suggest that the negative findings of the Honer 
study resulted from an inadequate dose of risperi-
done. I apologize for my mistake. I found no evi-
dence of bias in terms of pharmaceutical-indus-
try sponsorship on the efficacy data from the 
randomized, controlled trials comparing second-
generation with first-generation antipsychotic 
agents. All these drugs are effective, but random-
ized, controlled trials establish clozapine as the 
most efficacious.1,2 However, the initial Europe-
an experience found clozapine associated with 
agranulocytosis in about 1 to 2 percent of the pa-
tients (one third of cases were fatal). I agree with 
Dr. Gerson’s conclusions. Mandatory monitoring 
of white-cell counts does indeed greatly minimize 
the risk of this complication.
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University of Illinois at Chicago
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Hypertonic Saline for Cystic Fibrosis
To the Editor: We question the selection by El-
kins et al.1 and Donaldson et al.2 (Jan. 19 issue) 
of 7 percent hypertonic saline, which can result 
in bronchoconstriction, in these studies of thera-
py for cystic fibrosis. Elkins et al. report a fall of 
94 ml in the forced expiratory volume in one 
second (FEV
1
) after the first dose of medication, 
which is greater than the reported final improve-
ment in FEV
1
 of 68 ml. Conversely, Donaldson et 
al. do not specify any change in FEV
1
 with the 
use of 7 percent hypertonic saline. Robinson et al.3 
have compared mucociliary clearance with the 
use of different concentrations of hypertonic sa-
line and did not find any difference in efficacy 
between solutions of 3 percent and 7 percent hy-
pertonic saline solutions. We have shown that the 
use of 3 percent hypertonic saline is effective and 
has the additional advantage of not causing a 
substantial change in FEV
1
, oxygen saturation, or 
symptom score.4 Hence, the choice of the strength 
of the hypertonic saline solution administered 
should be based on the potential effects of hyper-
tonic saline on pulmonary function, oxygen satu-
ration, palatability, and the patient’s preference.
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To the Editor: Donaldson and colleagues re-
port that hypertonic saline after pretreatment with 
amiloride did not result in a sustained increase in 
mucus clearance or improvement in lung func-
tion or respiratory symptoms because of inhibi-
tion of apical membrane water permeability. 
Animal airways have a moderate osmotic water 
permeability and express aquaporin water chan-
nels, one of which is aquaporin-3.1-3 In Table 1 of 
their article, the authors report that 50 percent of 
the patients in each of the two study groups re-
ceived inhaled steroids concomitantly. Corticoste-
roids have been found to induce the expression of 
aquaporin-3 in A549 cells, a human airway epi-
thelial-cell line derived from lung adenocarcino-
ma, in vitro.3 In addition, hypertonicity induces 
the expression of aquaporin-3 in Madin–Darby 
canine-kidney cells, a renal epithelial-cell line, in 
vitro.4 Perhaps patients receiving concomitant 
treatment with inhaled steroids should have been 
studied separately, in order to identify the possi-
ble contribution of aquaporin-3 overexpression 
to hypertonic saline treatment.
Sotirios Zarogiannis, B.Sc.
Chrissi Hatzoglou, M.D., Ph.D.
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To the Editor: The importance of the volume of 
the airway surface liquid in the pathophysiology 
of cystic fibrosis lung disease is supported by the 
findings of Elkins et al. and Donaldson et al. As 
pointed out in the accompanying editorial by 
Ratjen,1 the mechanism of the prolonged action 
of inhaled hypertonic saline remains to be eluci-
dated. We suggest that one mechanism pertains 
not to the volume of the airway surface liquid but, 
rather, to the effect of sodium ions on the viscos-
ity of the mucus gel. Studies of gastrointestinal 
mucins have shown that calcium is the main cat-
ion that binds to mucins; the interaction increas-
es the viscosity of the mucus gel.2 Calcium bind-
ing to mucin is displaced by hypertonic sodium 
chloride.3 Whether these observations pertain to 
airway mucins in patients with cystic fibrosis re-
quires further investigation. Since mucus hyper-
viscosity has been implicated in the intestinal, 
hepatobiliary, and pancreatic manifestations of 
cystic fibrosis, hypertonic saline might be useful 
for the prevention of complications in these or-
gans as well.
Rahul Kuver, M.D.
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Drs. Bye and Elkins reply: Drs. Aziz and Kaste-
lik question the selection of a concentration 
higher than 3 percent in our phase 3 trial of in-
haled hypertonic saline for cystic fibrosis. On the 
basis of the single-intervention studies they cite, 
we agree that a single dose of 3 percent saline in-
creases the weight of sputum expectorated and im-
proves mucociliary clearance to a degree similar 
to 7 percent saline. However, the primary outcome 







because it correlates with mortality in patients 
with cystic fibrosis.1 When designing the trial, 
we therefore also considered the data from phase 
2 trials that examined the effect of the regular 
use of hypertonic saline on lung function. We were 
unable to find evidence of an improvement in lung 
function with 3 percent saline. At higher concen-
trations, however, there was evidence of a benefit 
in both mucociliary clearance and lung function.2 
Our observations that 7 percent saline did not re-
sult in excessive side effects in clinical practice 
and in previous trials were supported by others.3 
We therefore chose 7 percent saline as the inter-
vention for our trial. Further studies comparing 
various concentrations, as well as dosages and de-
livery systems, would help to refine the treatment 
protocol.
Drs. Aziz and Kastelik also express concern 
that the 94-ml fall in FEV
1
 after the first dose of 
hypertonic saline was greater than the final im-
provement in FEV
1
, of 68 ml. As stated in the ar-
ticle, premedication with a bronchodilator resulted 
in a 60-ml improvement in FEV
1
 that limited the 
effective fall from baseline. We also stated that 
the final improvement of 68 ml was relative to 
baseline. Thus, any initial fall in FEV
1
 was recov-
ered, and then an additional average improvement 
of 68 ml was achieved.
Drs. Kuver and Lee suggest that a possible 
mechanism of action of hypertonic saline in the 
lungs is the effect of sodium ions on the viscos-
ity of the airway mucus gel. Other authors have 
examined this possibility, as mentioned in our 
article and as reviewed more comprehensively by 
King.4 Our trial did not provide any data to indi-
cate whether hypertonic saline would have an ef-
fect on mucins from other organs.
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Dr. Donaldson and colleagues reply: Mr. 
Zarogiannis et al. point out that corticosteroids 
and hypertonicity up-regulate aquaporin-3 and 
speculate that the use of inhaled corticosteroids 
could have influenced responses to amiloride, 
hypertonic saline, or both. Because the effect of 
amiloride on water transport was discovered only 
after the completion of our clinical trial, we nei-
ther excluded nor studied separately patients re-
ceiving inhaled corticosteroids. Reassuringly, 
inhaled corticosteroid use was balanced in the ran-
domized groups, and all subjects were exposed 
to hypertonic saline, making it unlikely that an 
effect on aquaporin-3 greatly influenced the trial 
outcomes. Finally, recent in vitro experiments in 
our laboratory (unpublished data) suggest that 
water transport by means of aquaporin-3 is not at-
tenuated by amiloride.
Drs. Aziz and Kastelik question the selection 
of 7 percent (as compared with 3 percent) saline. 
They refer to their own study, which reported 
safety with a single dose of 3 percent saline used 
for sputum induction. Because the mass of salt 
deposited on airway surfaces determines the mag-
nitude of the increase in the volume of airway 
surface liquid, we sought to use the highest con-
centration of hypertonic saline that would be 
safe and well tolerated. Robinson et al.1 provided 
good evidence for a dose–effect relationship be-
tween hypertonic saline and mucociliary clear-
ance, despite the absence of a significant differ-
ence between the 3 percent and 7 percent groups. 
Twelve percent saline was poorly tolerated, how-
ever, because of oropharyngeal irritation. There-
fore, 7 percent saline was selected on the basis 
of the study by Robinson et al. and other short-
term studies of hypertonic saline in cystic fi-
brosis. In our study, we report FEV
1
 values at two 
hours after administration of the first dose of 
hypertonic saline — values that, in fact, increased 
from baseline, further supporting the assertion 
that 7 percent saline is well tolerated in patients 
with cystic fibrosis.
Drs. Kuver and Lee propose an alternative 
mechanism linking the use of hypertonic saline 
and stimulated mucociliary clearance. Displace-
ment by sodium of the calcium ions that bind 
mucins is postulated to explain the expulsion of 
mucins during exocytosis, and may influence the 
rheologic properties of mucus once secreted.2 In 
fact, we did invoke the “electrostatic effects” of 
hypertonic saline to explain acutely stimulated 
mucociliary clearance after amiloride plus inha-
lation of hypertonic saline, because in vitro data 
suggested that little increase in airway surface 
liquid volume occurs in this situation because amil-
oride blocks water transport. During treatment 
with hypertonic saline without amiloride, howev-
er, isotonicity is restored rapidly (in approximately 
two minutes) in the airway lumen,3 suggesting 
that both the acute and the sustained effects on 
mucociliary clearance of placebo or hypertonic 
saline were due to improved hydration of secre-
tions, rather than to the persistence of a high salt 
environment.
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Dr. Ratjen replies: Drs. Kuver and Lee propose 
that the beneficial effect of inhaled hypertonic 
saline in cystic fibrosis may be due to the displace-
ment by sodium of calcium ions bound to mucins, 
thereby reducing the viscosity of airway mucus. 
Hypertonic saline has indeed been shown to im-
prove sputum rheology, and it is conceivable that 
changes in mucin ion composition contribute to 
this finding.1 However, changes in the mechani-
cal properties of mucus would not explain the pro-
longed effect of hypertonic saline on airway sur-
face liquid height in vitro, since these experiments 
were performed in the absence of a mucus layer. 
In addition, agents that merely change the rheol-
ogy of airway secretions do not affect mucocili-
ary clearance in cystic fibrosis. This is highlight-
ed by studies with recombinant human DNase, 
which reduces sputum viscosity but, unlike hyper-
tonic saline, does not increase mucociliary clear-
ance.2,3 These observations would therefore sup-
port the concept that hypertonic saline, rather 
than acting primarily as a mucolytic agent, im-
proves mucociliary clearance through an increase 
in airway surface liquid height.
Felix Ratjen, M.D., Ph.D.
Hospital for Sick Children
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Illness in Returned Travelers
To the Editor: Freedman et al. (Jan. 12 issue)1 
has called attention to hazards for travelers. As 
the authors state, the study does not reflect the 
full epidemiology of travelers’ diseases. There is 
a great danger that patients and practitioners who 
anticipate and strive to prevent the serious threats 
to health for travelers will mistakenly consider 
only infectious diseases. Physicians advising pa-
tients who are planning travel to tropical coun-
tries must warn them of the real burden of illness: 
premature death from injury.
In earlier studies of deaths of Americans over-
seas, some 10,000 deaths were analyzed accord-
ing to cause, age, and place of occurrence.2,3 There 
were 601 deaths from injuries and only 25 deaths 
caused by infectious diseases. Death rates from 
injuries in developing countries were consider-
ably higher than those in the United States. Simi-
lar findings came from an earlier study involving 
Peace Corps volunteers.4
Travel clinics would be seriously remiss if they 
did not counsel travelers on the dangers of inju-
ries. Advice to avoid motorcycles, small vehicles, 
unscheduled aircraft, and swimming in unfamil-
iar waters is essential to help protect travelers.5
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The authors reply: We concur with the point 
made by Bishai and Baker. The literature indi-
cates that about 25 percent of overseas deaths are 
from injury, with the remainder largely from natu-
ral causes.1,2 MacPherson et al. estimated that 
about 36 percent of all overseas deaths are pre-
ventable.1 As travel patterns have changed and 
adventure travel has increased, new studies are 
needed. An unanswered question is whether the 
risk of dying from causes other than natural ones 
while traveling overseas is different from that 
while staying home.
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Unprofessional Behavior among Medical Students
To the Editor: The real shocker in the report by 
Papadakis et al. (Dec. 22 issue)1 regarding disci-
plinary action by medical boards is the enormous 
prevalence of unprofessional behavior among 
medical students in the control group (nearly 20 
percent). If unprofessional students become un-
professional doctors, then we face a real crisis, 
with huge numbers of unprofessional physicians 
currently in practice.
Medical students are reflective of society at 
large. Lack of professionalism among medical 
students is hardly surprising when high schools 
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